Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Explore linked clinical trials.19 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications | cardiovascular disorder, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 2 | 2026-09-23 | NCT07835984 | |
| A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-09-23 | NCT07835971 | |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0195 Injection in Participants With or Without Elevated Lipoprotein(a) | Elevated Lipoprotein(a) | Not yet recruiting | Phase 1 | 2026-09-04 | NCT07804160 | |
| SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a) | Elevated Lp(a); Healthy Participants | Active, not recruiting | Phase 1 | 2026-08-04 | NCT07745114 | |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Not yet recruiting | Phase 2 | 2026-07-27 | NCT07729475 | |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Not yet recruiting | Phase 1 | 2026-07-23 | NCT07722299 | |
| A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 2 | 2026-07-21 | NCT07716618 | |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Phase 2 | 2026-06-17 | NCT07654140 | |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Phase 2 | 2026-06-15 | NCT07647133 | |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism | adrenal gland disorder, adrenal gland hyperfunction, endocrine system disorder, hyperaldosteronism, primary aldosteronism | Not yet recruiting | Phase 2 | 2026-06-12 | NCT07646535 | |
| A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens | Postmenopausal Women With Osteoporosis | Recruiting | Phase 2 | 2026-05-12 | NCT07579936 | |
| Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Not yet recruiting | Phase 1 | 2026-03-20 | NCT07486453 | |
| Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, bone disorder, metabolic disease, musculoskeletal system disorder, osteoporosis | Enrolling by invitation | Phase 1 | 2026-02-03 | NCT07384104 | |
| Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants | Healthy Participants | Recruiting | Phase 4 | 2025-09-16 | NCT07174830 | |
| Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients | Renal Anemia in Non-dialysis Chronic Kidney Disease | Not yet recruiting | Phase 4 | 2025-07-23 | NCT07079579 | |
| SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population | Uncontrolled Hypertension | Recruiting | Phase 1 | 2025-07-04 | NCT07051603 | |
| To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects | Pharmacokinetics | Active, not recruiting | Phase 1 | 2025-06-22 | NCT07030504 | |
| Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants | Bioequivalence | Not yet recruiting | Phase 1 | 2025-02-17 | NCT06830954 | |
| SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies | Hemic and Lymphatic Diseases, anemia, hematologic disorder | Recruiting | Phase 2 | 2024-12-17 | NCT06737081 |